Harkin Statement on Avandia FDA Advisory Panel Recommendation
Wednesday, July 14, 2010Kate Cyrul / Bergen Kenny (202) 224-3254
WASHINGTON, D.C. – Senator Tom Harkin (D-IA), Chairman of the Health, Education, Labor and Pensions (HELP) Committee, released the following statement regarding a review by the U.S. Food and Drug Administration (FDA) of potential risks associated with the drug AVANDIA (rosiglitazone maleate), which is a medication manufactured by GlaxoSmithKline to treat type 2 diabetes mellitus.
FDA is evaluating data, submitted in August 2009, from a large, long-term clinical study called the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD), which was designed to evaluate the cardiovascular safety of rosiglitazone. As part of its evaluation, FDA re-convened a Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee with the Drug Safety and Risk Management Advisory Committee to review and advise the agency on the totality of new and existing cardiovascular safety data on AVANDIA. Today, the Committee voted to keep the drug on the market with heightened warnings about its safety.
“AVANDIA is a widely used drug, and it is imperative that the risks associated with its use be properly understood and vetted,” said Harkin. “I urge FDA to carefully consider today’s deliberations by the Joint Advisory Committee, and to make a final decision on how best to protect consumers as soon as possible. The safety of those suffering with diabetes must be our primary concern.”
AVANDIA was originally approved for use by FDA in May 1999. In 2007, a cardiologist at the Cleveland Clinic, Dr. Steven E. Nissen, published a study that suggested the medications carried cardiovascular risks. Following that study, FDA left AVANDIA on the market, as recommended by its expert advisory committee, but directed GlaxoSmithKline to modify AVANDIA’s label to include a caution regarding heart attack risk.
- Harkin Statement on House Vote That Would Make College More Expensive for Millions of American Students [Chairman]
- Harkin Reintroduces FIT Kids Act to Combat Childhood Obesity and Promote Physical Activity [Chairman]
- Alexander Opposes Nominees to NLRB Who Remained on Board After Court Found Their Appointments Unconstitutional [Ranking Member]
- Senate Health Committee Passes Alexander and Colleagues’ Bill to Fix Responsibility for Safety of Sterile Compounded Drugs [Ranking Member]
- Harkin Statement on HELP Committee Approval of a Full Slate of Five Nominees to the NLRB [Chairman]
- Harkin Statement on HELP Committee Passage of the Pharmaceutical Compounding Quality and Accountability Act and the Drug Supply Chain Security Act [Chairman]